gefitinib has been researched along with luteolin in 2 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (luteolin) | Trials (luteolin) | Recent Studies (post-2010) (luteolin) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 2,402 | 15 | 1,648 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Markaverich, BM; Rodriguez, M; Shoulars, K; Vijjeswarapu, M | 1 |
Hagiyama, M; Inoue, T; Ito, A; Naito, Y; Nojima, H; Okamoto, A; Okuzaki, D; Ozaki, Y; Sakurai, MA; Sasakura, T; Tabara, H; Yabuta, N | 1 |
2 other study(ies) available for gefitinib and luteolin
Article | Year |
---|---|
Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Luteolin; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2010 |
Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Luteolin; Male; MicroRNAs; Models, Biological; Neoplasm Grading; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Quinazolines; Signal Transduction | 2014 |